

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/169,793	10/09/1998	CHARLES A. CONRAD	INGA.004 6075		
759	90 05/30/2006		EXAMINER		
MARK R. WISNER			MARTINELL, JAMES		
WISNER & ASSOCIATES 1177 WEST LOOP SOUTH			ART UNIT PAPER NUM		
SUITE 400			1634		
HOUSTON, TX	X 77027	DATE MAILED: 05/30/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)				
Office Action Summary		09/169,793		CONRAD, CHARLES A.				
		Examiner		Art Unit				
_		James Martinell		1634				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover	sheet with the co	rrespondence ad	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAISING SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS CO 36(a). In no event, hower will apply and will expire S , cause the application to	MMUNICATION wer, may a reply be time SIX (6) MONTHS from the become ABANDONED	Bly filed the mailing date of this c (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) filed on 11 Ju	ılv 2005.						
2a)⊠	This action is <b>FINAL</b> . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims							
4)🖂	4) Claim(s) 1-7 and 9-15 is/are pending in the application.							
	4a) Of the above claim(s) <u>1-6 and 12</u> is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
6)⊠	☑ Claim(s) 7,10,11 and 13-15 is/are rejected.							
	Claim(s) 9 is/are objected to.							
8)	Claim(s) are subject to restriction and/or	r election requirer	nent.		•			
Applicati	ion Papers	,						
. 9)□	The specification is objected to by the Examine	r						
			or b)⊠ objected t	to by the Examin	ner.			
10) $\boxtimes$ The drawing(s) filed on <u>09 October 1998</u> is/are: a) $\square$ accepted or b) $\boxtimes$ objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11)	The oath or declaration is objected to by the Ex	·	• • • • • • • • • • • • • • • • • • • •		` '			
Priority ι	under 35 U.S.C. § 119							
12)	Acknowledgment is made of a claim for foreign	priority under 35	U.S.C. § 119(a)-	(d) or (f)				
a) ☐ All b) ☐ Some * c) ☐ None of:								
71	1. Certified copies of the priority documents	s have been recei	ved.					
	Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the prior		• •		Stage			
	application from the International Bureau	•			-			
* 5	See the attached detailed Office action for a list	of the certified co	pies not received	d.				
			•	•				
Attachmen	t(s)							
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)								
_	ce of Draftsperson's Patent Drawing Review (PTO-948)			r No(s)/Mail Date e of Informal Patent Application (PTO-152)				
	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) or No(s)/Mail Date		Other:		O-132)			

Application/Control Number: 09/169,793

Art Unit: 1634

Claims 1-6 and 12 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on May 19, 2000.

The drawings are objected to for the reasons given in the Notice of Formal Drawings Required mailed August 11, 2000. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filling date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 7, 10, 11, and 13-15 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by any one of Mirochnitchenko et al (J. Biol. Chem. 269: 2380 (1994)), Miyata et al (EP 0 532 380), or Inouye et al (EP 0 562 206). Each of the references discloses vectors for the *in vivo* production of single stranded antisense DNA utilizing a vector that contains a template for antisense DNA flanked by the inverted repeats and employing a cloned RT gene for production of reverse transcriptase and thus, single stranded DNA. For example, see Mirochnitchenko et al "Results and Discussion" section, Miyata et al, pages 4-10, and Inouye et al, pages 5-14. This rejection is repeated for reasons already of record (*e.g.*, Office action mailed May 8, 2001, page 1, last full paragraph). Applicant's arguments (response filed July

Application/Control Number: 09/169,793

Art Unit: 1634

11, 2005, pages 1-2) are not convincing. Each of the cited regions of the references discloses all of the elements that are required in the claims. For example, msDNAs necessarily contain tandem repeats because they form stable stem-loop structures (*e.g.*, see Inouye et al at page 5, lines 30-49). In addition, a primer binding site may be broadly interpreted as any stretch of nucleic acid since any small piece of nucleic acid may be used as a primer. That ssDNA is produced is evident in the titles of each of the references. Applicant's arguments are not commensurate with the breadth of the claims. Claim 7 is considerably broader than what is described in the application. For example, see page 6, lines 4-21 and page 11, lines 10-29.

Claims 7, 10, 11, and 13-15 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Miyata et al (U.S. Patent No. 5,436,141). The reference discloses vectors for the *in vivo* production of single stranded antisense DNA utilizing a vector that contains a template for antisense DNA flanked by the inverted repeats and employing a cloned RT gene for production of reverse transcriptase and thus, single stranded DNA. For example, see columns 5-14 and claims 1-45. This rejection is repeated for reasons already of record (*e.g.*, Office action mailed May 8, 2001, paragraph bridging pages 1-2). Applicant's arguments (response filed July 11, 2005, pages 1-2) are not convincing. Each of the cited regions of the reference discloses all of the elements that are required in the claims. For example, msDNAs necessarily contain tandem repeats because they form stable stem-loop structures (*e.g.*, see column 6, lines 11-28). In addition, a primer binding site may be broadly interpreted as any stretch of nucleic acid since any small piece of nucleic acid may be used as a primer. That ssDNA is produced is evident in the titles of each of the references. Applicant's arguments are not commensurate with the breadth of the claims. Claim 7 is considerably broader than what is described in the application. For example, see page 6, lines 4-21 and page 11, lines 10-29.

Claim 9 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in

Art Unit: 1634

the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114.

Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Martinell whose telephone number is (571) 272-0719.

The examiner works a flexible schedule and can be reached by phone and voice mail.

Alternatively, a request for a return telephone call may be e-mailed to <a href="mailto:james.martinell@uspto.gov">james.martinell@uspto.gov</a>. Since e-mail communications may not be secure, it is suggested that information in such requests be limited to name, phone number, and the best time to return the call.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735.

Art Unit: 1634

## **OFFICIAL FAX NUMBER**

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Any Official Communication to the USPTO should be faxed to this number.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

James Martinell, Ph.D. Primary Examiner Art Unit 1634

5/18/06